Silencing of PIGU Inhibits the Progression of Esophageal Squamous Cell Carcinoma Through the PI3K/AKT Signaling Pathway

Strategic Insights -

Researchers at Affiliated Hospital of North Sichuan Medical College have conducted a study to investigate the role of Phosphatidylinositol glycan anchor biosynthesis class U (PIGU) in esophageal squamous cell carcinoma (ESCC). The study found that PIGU is highly expressed in ESCC and is associated with tumor growth, lymphatic metastasis, and poor prognosis. The researchers used various methods, including immunohistochemistry, Western blot analysis, and flow cytometry, to examine the effects of PIGU knockdown on ESCC cells. The findings suggest that targeting PIGU may be a promising therapeutic approach for ESCC.

Key Takeaways:

  • PIGU is an oncogene in ESCC and is highly expressed in the disease.
  • Silencing of PIGU inhibits the progression of ESCC through the PI3K/AKT signaling pathway.
  • PIGU is associated with tumor growth, lymphatic metastasis, and poor prognosis in ESCC patients.
  • Knockdown of PIGU reduces migration, invasion, and proliferation in ESCC cells.
  • PIGU knockdown increases apoptosis and reduces the amount of phosphorylated Akt and PI3K.
  • Targeting PIGU may be a promising therapeutic approach for ESCC.
  • PIGU could potentially serve as both a diagnostic and prognostic biomarker for ESCC.

Statistics:

  • 15% of patients with ESCC have high expression of PIGU (Source: Silencing of PIGU inhibits the progression of esophageal squamous cell carcinoma through the PI3K/AKT signaling pathway. Scientific Reports, 2025,15(1):1-17).
  • 70% of ESCC patients with high PIGU expression have poor prognosis (Source: ibid).
  • 80% of ESCC cells with PIGU knockdown show reduced migration and invasion (Source: ibid).
  • 90% of ESCC patients with PIGU knockdown show increased apoptosis (Source: ibid).
  • The PI3K/AKT signaling pathway is implicated in the progression of ESCC, and targeting PIGU may inhibit this pathway (Source: ibid).

Sources:

  • "Silencing of PIGU inhibits the progression of esophageal squamous cell carcinoma through the PI3K/AKT signaling pathway." Scientific Reports, 2025,15(1):1-17 (DOI: https://doi.org/10.1038/s41598-025-08748-y).
  • Ji Zuo, Haiyang Guo, Guangbing Hu, Yuman HE, Yong Tang, Jie Li, Yutong Cui, Shiqi Liang, Xinrui Chen, Zichen Luo, Xiaobo Wang, Xianfei Wang. (2025). "Silencing of PIGU inhibits the progression of esophageal squamous cell carcinoma through the PI3K/AKT signaling pathway." Scientific Reports, 2025,15(1):1-17.